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INTRODUCTION
Recently, there has been an increase in the numbers of breast
cancer diagnosed in Korea. Breast cancer patients with the
same stage of disease can have markedly different treatment
responses and overall outcome. Furthermore, the biology of
breast cancer remains poorly understood. As a result, breast
cancers have become an increasingly significant problem in
the evaluation and management of patients. 
The cDNA microarray technology allows us the parallel
analysis of the expression of thousands of genes to address
complex questions in tumor biology (1). Systematic investi-
gation of expression pattern of thousands of genes in breast
cancers using cDNA microarray, and their correlation to spe-
cific features of phenotypic variation, might provide the basis
for an improved taxonomy of breast cancer (2-9). The ability
to use appropriate profiles of gene expression could add enor-
mous detail to the few known biological attributes in tumor
characterization.
Elevated levels of  -catenin have been associated with poor
prognosis in breast cancer (10). However, the mechanisms
by which  -catenin confers the more aggressive biological
behavior are poorly understood in breast cancer.  -catenin
is a multifunctional protein that plays an essential role in the
transduction of Wnt signaling and a component of the cad-
herin cell adhesion complex (11, 12). In the absence of Wnt
signaling, the cytoplasmic level of  -catenin is kept low
through interaction with a protein complex comprised of
adenomatous polyposis coli (APC), Axin, protein phosphatase
2A (PP2A), and glycogen synthase kinase 3 (GSK3 ),
where  -catenin is phosphorylated by GSK3 (13, 14). Acti-
vation of Wnt signaing leads to the inactivation of GSK3
resulting in accumulation of cytoplasmic  -catenin. At ele-
vated cytoplasmic levels,  -catenin translocates to the nucle-
us and cooperates with a member of the T cell factor (Tcf)/lym-
phocyte enhancer binding factor (Lef) family of high-mobili-
ty group box transcription factors to activate expression of
target genes (13).
In this study, cDNA microarray analysis of approximately
4,600 cDNAs was performed to examine the gene expression
profile in breast cancer on a more global scale. Immunohisto-
chemical study was used to further demonstrate the specificity
of the cDNA microarray results and to confirm the differen-
tial expression genes that were known to have important role
in -catenin  regulation. 
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Gene Expression Profiling of Breast Cancers with Emphasis of 
-Catenin Regulation
To gain molecular understanding of carcinogenesis of breast cancer, gene expres-
sion profiles were analyzed using cDNA microarray representing 4,600 cDNAs in
10 breast cancer samples and the adjacent noncancerous breast tissues from the
same patients. The alterations in gene expression levels were confirmed by reverse-
transcription PCR in four randomly selected genes. Genes that were differently
expressed in cancer and noncancerous tissues were identified. 106 (of which 55
were known) and 49 (of which 28 were known) genes were up- or down-regulated,
respectively, in greater than 60% of the breast cancer samples. In cancer tissues,
genes related to cell cycle, transcription, metabolism, cell structure/motility and signal
transduction were mostly up-regulated. Furthermore, three cancer tissues showing
immunohistochemically aberrant accumulation of  -catenin in the nucleus and/or
cytoplasm revealed down-regulation of Siah and Axin genes and up-regulation of
Wnt and c-myc genes. These findings were highly consistent with Wnt signaling path-
way associated with  -catenin regulation previously suggested by others. Our stud-
ies, therefore, provide not only a molecular basis to understand biological process-
es of breast cancer but also useful resources to define the mechanism of  -catenin
expression in tumorigenesis of breast cancer.
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Tissue samples and RNA preparation
Ten pairs of breast cancer tissues and corresponding adja-
cent noncancerous breast tissues were obtained from 10 female
patients who underwent lumpectomy or mastectomy at Dong-
A University Medical Center between August 2001 and
February 2002. Informed consent was obtained from patients
to use their operated specimens and clinicopathological data
for research purposes. The samples were anonymized before
study. A pathologist dissected tissue samples from surgical
specimens with special care for minimal contamination
between cancer and noncancerous tissues and samples were
immediately frozen in liquid nitrogen and stored at -80℃.
Total RNA was isolated from the frozen tissue by using TRI
REAGENT (Molecular Research Center, Inc., OH, U.S.A.).
The remaining parts of specimens were fixed with 10%
buffered formalin and the paraffin sections were stained with
hematoxylin and eosin. Histological classifications were deter-
mined by two pathologists in each case. When there was a
discrepancy in interpretation of pathologic grade between
the two observers, the hig- her grade was selected as repre-
sentative grade.
These clinical and histopathological features were summa-
rized in Table 1.
Microarray analysis
Ten pairs of breast cancer and corresponding adjacent non-
cancerous breast tissues were analyzed by MAGICTM microar-
ray (Macrogen, Inc., Korea). This array contains 4,600 cDNAs,
isolated from cDNA library of human breast cancer, and is
composed of 4,370 known genes and 230 unknown genes
(EST). For synthesizing double-stranded cDNA probe, label-
ing kit provided by Macrogen was used. Microarray hybridiza-
tion was performed according to manufacturer’s instructions.
Briefly, reverse transcription was performed on 30-50  g of
total RNAs for 1 hr at 42℃with a T7-oligo (dT) 24 primer
and Superscript II reverse transcriptase (Life Technologies,
Inc., Rockville, MD, U.S.A.). Second-strand cDNA synthe-
sis was performed for 2 hr at 16℃ with Escherichia coli DNA
polymerase I, DNA ligase, and RNAse H (Life Technolo-
gies, Inc., Rockville, MD, U.S.A.), followed by incubation in
solulion containing 50 mmol/L NaOH/ 0.1 mmol/L EDTA
for 10 min at 65℃, which caused degradation of the rRNA
and tRNA. After phenolchloroform extraction in vitro, tran-
scription was performed for 6 hr at 37℃using Cy5UTP and
Cy3CTP, and a T7-Megascript kit (Ambion, Inc., Austin,
TX, U.S.A.), and then fragmented for 35 min at 95℃. Hybri-
dization (at 62℃for 16 hr) with the labeled cDNA in 6 mL
of hybridization solution (6× SSC, 0.2% SDS, 5× Den-
hardt solution, 1 mg/mL salmon sperm DNA) was followed
by stringent washing (0.05× SSC, 0.2% SDS, at 58℃ for
1 hr).
Data analysis 
Images were analyzed by using the ImaGeneTM analysis
software (BioDiscovery, Inc., Marina del Rey, CA, U.S.A.).
Spots showing no signal, or obvious defects, were excluded
from the analysis. The local background was subtracted from
the remaining spots and the ratios of net fluorescence from
the Cy5-specific channel to the net fluorescence from the
Cy3-specific channel were calculated for each spot. For this
purpose, we determined transcript abundance using a custom
algorithm, and the data set was trimmed of genes expressed
at extremely low levels; that is, a gene was excluded if its 70
percentile value was less than 0.2 in 2 [log (tumor/normal)]
value. The results represented RNA expression in cancer
relative to the corresponding noncancerous breast tissue.
A two-way pairwise average-linkage cluster analysis as an
unsupervised clustering was applied. The cluster analysis was
performed with Cluster 2.11, and the resulting expression
map was visualized with TreeView 1.5. A set of microarray
containing 4,600 cDNAs in duplicate was hybridized with
a mixture of Cy3-labeled cDNA probes corresponding to can-
cer tissues and Cy5-labeled cDNA probes corresponding to
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Case No. Age (yr) Tumor size (cm) Histologic type Pathologic grade LN -catenin ER PR
1 51 5.5 Infiltrating ductal ca 3 + Membranous --
2 43 6 Intraductal ca 1 - Membranous + +
3 47 1.5 Infiltrating ductal ca 1 + Membranous + -
4 46 2.5 Infiltrating ductal ca 1 - Membranous + -
5 40 4.5 Infiltrating ductal ca 3 - Aberrant --
6 58 1.5 Infiltrating ductal ca 2 + Aberrant + -
7 41 2.5 Infiltrating ductal ca 1 + Aberrant + +
8 50 3 Infiltrating ductal ca 3 + Membranous + +
9 43 2 Infiltrating ductal ca 2 - Membranous --
10 43 3 medullary ca 3 - Membranous + +
Table 1. Clinicopathologic summary of the breast cancer patients
Pathologic grade, histologic grade by Elston & Ellis method (35); LN, axillary lymph node metastasis; ER, estrogen receptor; PR, progesterone receptor;
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noncancerous tissues. To identify genes with significantly dif-
ferent expressions in breast cancer and noncancerous tissues,
rational Cy3/Cy5 cut off values were determined. The differ-
entially expressed genes, identified from cDNA microarray
comparisons, were assigned to a modification of the NCBI
Clusters of Orthologous Gene classification by searching the
OMIM and PubMed databases (15). The genes were then
assigned to 10 known functions (cell cycle regulator, transcrip-
tion, oncogene/tumor suppressor gene, metabolism, cell struc-
ture/motility, signal transduction, gene/protein expression,
DNA repair, angiogenesis, and immunology) and a miscel-
laneous category.
Semiquantitative RT-PCR
Single-stranded cDNA was synthesized with oligo (dT)
primer in a 20- L reaction, from 5  g of total SuperScript
Preamplification System for First Strand cDNA Synthesis
System (Life Technologies, Inc., Rockville, MD, U.S.A.) and
diluted up to final volume of 80  L. PCR was then performed
with 1  L of cDNA, for 1 cycle of 94℃ for 2 min, followed
by 25 cycles of 94℃for 30 sec, 55℃for 30 sec, and 72℃for
1 min, using a gene-specific primer and Taq polymerase. 
Primers were as follows; U76248 (Siah) sense, 5′ -AAGC-
TGTGATGTCCCATCTC-3′ , antisense, 5′ -AGTCTGTAG-
GCAAAGTTCTC-3′ , AF009674 (Axin) sense, 5′ -TGAGA-
ACTCCAGACCGTTGT-3′ , antisense, 5′ -TGCACATACC-
TCTGCTTGGA-3′ , D79995 sense, 5′ -GGATGACGTGAT-
ACTCAATG-3′ , antisense, 5′ -GGTAGAAAGGCTGGGC-
TCTT-3′ , X06825 (Tropomyosin 2 ) sense, 5′ -CTGGTGA-
TCCTGGAAGGAGA-3′ , antisense, 5′ -GCTTCTCCTCC-
AACAGTTTG-3′ .
Amplification of the correct target DNA was confirmed
by mobility of gel electrophoresis and sequencing after sub-
cloning into pGEM-T easy vector (Promega, Madison, WI,
U.S.A.).  -actin was used as an internal control to confirm equal
amount between the templates.
Immunohistochemical stain
Paraffin-embedded 5  m-thick breast tumor sections were
analyzed for  -catenin expression by immunohistochemical
staining. Immunohistochemical staining was performed using
monoclonal mouse anti-(human Ig) antibody directed against
-catenin (1:30, Zymed, CA, U.S.A.). Deparaffinization of
all sections was performed through a series of xylene baths
and rehydration was performed through graded alcohols. To
enhance the immunoreactivity, microwave antigen retrieval
at 750 W for 30 min in citrate buffer (pH 6.0) was performed.
After blocking the endogenous peroxidase activity with 5%
hydrogen peroxidase for 10 min, the primary antibody incu-
bation for  -catenin was performed at room temperature for
100 min. Detection of the immunoreactive staining was car-
ried out by the avidin-biotin-peroxidase complex method
using Histostain-plus kit (Zymed, CA, U.S.A.). The antigen-
antibody reaction was visualized using 3-amino-9-ethylcar-
bazole as a chromogen. The Mayer’s hematoxylin counterstain
was performed.
Immunohistochemical staining for  -catenin expression
was divided into two groups according to their immunohis-
tochemical patterns by a pathologist: normal membranous
pattern seen in non-neoplastic epithelium and aberrantly
accumulated pattern showing nuclear and/or cytoplasmic
staining with or without membranous staining.
RESULTS
Expression profiling revealed differentially expressed
genes in breast cancer and noncancerous tissues
We categorized ten pairs of breast cancer by comparing the
global gene expression patterns of cancer and noncancerous
tissue after data trimming. Of the 4,600 genes, a total of 1,084
genes was left after data trimming. By unsupervised hierar-
chical clustering based on 1,084 genes, the cancer and non-
cancerous tissues were successfully distinguished (data not
shown). However, this algorithm using most of the genes on
the array would not classify samples among cancer tissues by
subgroups associated with clinical and histopathological fea-
tures including age, tumor size, status of axillary lymph nodes,
histologic type of the tumor, pathologic grade, and hormone-
receptor status. 
When cut off values were set to 2.0, for the ratio between
the cancerous and noncancerous tissues, 106 (of which 55 were
known) and 49 (of which 28 were known) genes or cDNA
were up- or down-regulated, respectively, in >60% of the
breast cancer samples. These genes were classified in terms
of 10 functions (cell cycle regulator, transcription, oncogene/
tumor suppressor gene, metabolism, cell structure/motility,
signal transduction, gene/protein expression, DNA repair,
angiogenesis, and immunology), as shown in Table 2. In the
cancerous tissues, the genes related to cell cycle regulator, tran-
scription, metabolism, cell structure/motility and signal trans-
duction were mostly up-regulated. We identified consistent
results of several genes that had some roles in cancer biology
previously suggested by other workers, including pituitary
tumor-transforming gene (PTTG) (16), histone acetyltrans-
ferase (HAT) (17), c-src tyrosine kinase (CSK) (18), and insu-
lin-like growth factor binding protein (7).
Validation of DNA microarray by semiquantitative 
RT-PCR
To verify the reproducibility of these gene lists, we perform-
ed semiquantitative RT-PCR using the same RNA used in
the microarray analysis. Ten pairs of the cancerous and corre-
sponding noncancerous tissue samples were analyzed using278 M.S. Roh, S.H. Hong, J.S. Jeong, et al.
Function Accession No. Gene 2 log (T/N) Frequency
Cell cycle regulator D79995 KIAA0173 gene product -1.16 7
NM_012330 Histone acetyltransferase -1.3 6
NM_11722 Deoxynucleotidyltransferase -2.17 6
D14678 Kinesin-like 2 4.81 7
X66365 Cyclin-dependent kinase 6 2.74 7
U76248 Seven in absentia (Drosophila) homolog2 2.64 7
AF086947 Dynectin 1 2.76 6
U40705 Telomerin repeat binding factor 2.72 6
AB017430 Kinesin-like 4 2.67 6
NM_018667 Neutral sphingomyelinase II 2.32 6
AF095289 Pituitary tumor-transforming 3 1.8 6
X14850 H2A histone family, member X 1.48 6
Transcription NM_016331 Zinc finger protein ANC-2H01 2.24 9
U09412 Zinc finger protein 134 2.59 8
NM_013242 Similar to mouse Glt3 2.4 8
Oncogene/tumor suppressor gene AJ250014 KIAA0849 protein -1.6 7
K02276 Translocated t(8;14) c-myc oncogene -1.07 6
Y09160 Rho guanine nucleotide exchange factor 1 2.74 7
AF009674 Axin 1.53 7
Metabolism NM_015831 Acetylcholinesterase -1.48 6
Z25535 Nucleoporin 153 kDa -1.67 6
S69232 Electron-transferring-ubiquinone oxidoreductase -2.55 6
X59960 Sphingomyelin phosphodiesterase 1 3.26 7
M91211 Advanced glycosylation end product 2.92 7
X69433 Isocitrate dehydrogenase 2 2.21 7
AF069250 Acid-inducible phosphoprotein 2.33 6
AF064254 VLCS-H1 protein 11.5 6
Cell structure/Motility U61234 Tubulin-specific chaperone c -2.6 7
X06825 Tropomyosin 2 (beta) -1.18 6
M60922 Flotillin 2 -1.97 6
AB006780 Lectin 3.34 8
X14420 Collagen, type III, alpha 1 4.61 7
U80184 Flightless I (Drosophila) homolog 3.32 7
U33931 Erythrocyte membrane protein band 7.2 2.69 7
AF006087 Actin related protein 2/3 complex, subunit 4 1.93 6
Signal transduction L28824 c-src tyrosine kinase -1.43 7
AF078103 Develpomentally regulated GTP binding protein -1.81 7
AF263541 Dual-specificity tyrosine-(Y)-phophatase -2.46 7
M35878 Insulin-like growth factor binding protein -1.2 6
AF189009 Ubiquilin 2 -1.83 6
AF070599 Protein phosphatase 1 3.98 7
NM_004409 Dystrophia myotonica-protein kinase 3.28 7
U10099 POM-ZP3 mRNA 2.98 7
AF114012 Tumor necrosis factor (ligand) superfamily 2.61 7
U02680 Protein tyrosine kinase 9 3.03 6
AB014561 95kDa retinoblastoma protein binding protein 3.02 6
X78947 Connective tissue growth factor 1.37 6
Gene/protein expression U46571 Tetratricopeptide repeat domain 2 -2.06 8
NM_020365 Eukaryotic translation initiation factor -1.51 7
X70944 Splicing factor proline/glutamine rich -2.97 7
X76013 Glutamyl-tRNA synthetase -2.08 6
AB014546 Ring finger protein 8 4.34 7
NM_014018 Mitochondrial ribosomal protein 4.36 6
D13641 KIAA0016 3.76 6
DNA repair NM_016042 CGI-102 protein 3.56 8
M74905 N-methylpurine-DNA glycosylase 2.39 7
(Table 2, continued next)
Table 2. Representative differential expression in breast cancer, defined a 2-fold or greater change relative to expression in noncancer-
ous tissues, for various functional classes of genesfour randomly selected genes; U76248 (Siah), AF009674
(Axin), D79995, and X06825 (Tropomysin 2 ). Of these
genes, two genes associated with  -catenin regulation, Siah,
the mammalian homologue of Drosophila seven in absentia,
and Axin, were included. The results of the breast cancer genes
found from the semiquantitative RT-PCR analyses were mostly
consistent with those from the microarray studies (Fig. 1).
Genes associated with  -catenin regulation
When we reviewed genes that were differentially expressed
in cancer and noncancerous tissue (Table 2), we could readily
identify genes associated with  -catenin regulation. Three
cancerous tissues (case 5-7) showing immunohistochemically
aberrant accumulation of  -catenin revealed down-regulation
of Siah and Axin genes and up-regulation of Wnt and c-myc
genes. Of the remaining seven cancerous tissues without aber-
rant -catenin expression, four cases (case 1, 2, 8, 9) showed
that the results of the expression of these genes were vice versa
and remaining three cases (case 3, 4, 10) showed inconsistent
findings (Fig. 2, Table 3).
DISCUSSION
We have globally analyzed gene expression of breast can-
cer and noncancerous tissues to elucidate the characteristic
changes associated with the carcinogenesis and progression
in breast cancer. The cancer and noncancerous tissues were
distinguished by gene expression profiling. In the cancer tis-
sues, genes related to cell cycle, transcription, metabolism,
cell structure/motility and signal transduction were mostly
up-regulated in this study. We categorized ten pairs of breast
cancer by comparing the global gene expression patterns of
cancer and noncancerous tissue after data trimming. In this
study, genes with expression ratios that varied at least 2-fold
between the cancer and noncancerous tissues in 60% of the
samples were selected. Although it resulted in the loss of
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Function Accession No. Gene 2 log (T/N) Frequency
DNA repair J04973 Human cytochrome bc-1 complex core protein II 2.33 7
U12134 RAD52 (S. cerevisiae) homolog 2.4 6
Angiogenesis AF035121 Kinase insert domain receptor -2 6
U03644 CBF1 interacting corepressor 2.46 7
Immunology X14723 Clusterin -1.9 8
X53961 Lactotransferrin -2.19 7
AF110908 TNF receptor-associated factor 3 2.81 6
U12255 Fc fragment of IgG, receptor, transporter 2.3 6
X57809 Immunoglobulin lambda locus 1.73 6
J03909 Interferon, gamma-inducible protein 30 1.42 6
Table 2. (continued from the previous page) Representative differential expression in breast cancer, defined a 2-fold or greater change
relative to expression in noncancerous tissues, for various functional classes of genes
2 log (T/N), 2 log (Tumor/Noncancerous tissue).
2 log (T/N)
Case No.
Wnt-1 Siah Axin c-myc
1 -0.8 1.9 1.5 -1.5
2 -1.3 2.3 1.4 -1.5
3 F 3.5 0.6 -1.7
4 F 3.1 2.1 1.3
5 0.8 -0.6 -0.6 1.7
6 0.7 -0.8 -0.6 1.5
7 1.2 -1.4 -1.3 1.8
8 -1.8 4.1 2 -1.2
9 -1.9 2.1 1.6 -1.2
10 2 1.5 1.5 -2.5
Table 3. Differential expression pattern of genes associated with
-catenin regulation according to the immunohistochemical
findings for  -catenin
2 log (T/N), 2 log (Tumor/Noncancerous tissue); F, failed.
A Case 
No.
1
2
3
4
5
6
7
8
9
10
NT
B
NT
C
NT
D
NT
Fig. 1. The results of semiquantitative RT-PCR for the 4 tested genes
in the 10 breast cancer tissues and the noncancerous tissues, con-
sisting with those from the microarrary studies. N, noncancerous
tissue; T, tumor tissue; A, U76248 (Siah); B, AF009674 (Axin); C,
D79995; D, X06825 (Tropomyosin 2 ).some information, trimming in this manner decreased the
possibility that the clustering algorithm would be strongly
influenced by genes with little or no expression.
Most of the genes associated with the cell cycle were up-
regulated, and examplified by the cyclin-dependent kinase
6 (CDK6) and PTTG. CDK6 is considered as a cdc-2 related
kinase, which can play roles in the regulation of the mam-
malian cell cycle. The cyclin D/CDK6 complex phosphory-
lates the retinoblastoma protein. Under-phosphorylated pRb
binds to the E2F family of transcription factors. Phosphory-
lation of the pRb unshackles the E2F proteins, which in turn
activates the transcription of several genes whose products
are essential for progression through the S phase (19). Because
the state of the pRb phosphorylation is crucial in determin-
ing the cell cycle progression, the up-regulation of CDK6 in
cancer tissues was not unexpected. PTTG has been identified
as a key protein in mitotic regulation (20) and is highly ex-
pressed in pituitary tumor (21) and other neoplasms (22, 23).
PTTG protein has been recognized as a mammalian securin
protein that maintains binding of sister chromatids during
mitosis. Overexpression of a nondegradable PTTG disrupts
sister chromatid separation. PTTG overexpression results in
genetic instability (24). Puri et al. (25) revealed a high level
of expression of PTTG1 mRNA in both seminomatous and
non-seminomatous testicular tumors, epithelial cell, sex-cord
stromal cell, and germ cell tumors of the ovary, and in situ
and invasive ductal carcinoma of the breast. In this study of
breast cancer, PTTG was up-regulated in the cancerous tissue,
which agrees with the results from a previous study (25) and
suggests a certain role in tumorigenesis of breast cancer. On
the other hand, the HAT directly links chromatin modifica-
tion to genetic activation and has also important activities
in many cellular processes including cell cycle progression,
transcription and DNA replication (17). Developmental aber-
rations in mice and certain human cancers are associated with
HAT mutations, further highlighting the important of these
enzymes to normal cell growth and differentiation (26). In
our study, this gene was down-regulated in cancer tissue which
is consistent with the mechanism underlying tumor forma-
tion of mutations of HAT genes involved with the regulation
and control of the cell cycle.
The loss of tumor suppressor gene is a key event in many,
possibly all, human tumors, as the physiological function of
these genes are in the regulation of normal cell growth includ-
ing the cell cycle and nuclear transcription. We have identi-
fied a tumor suppressor gene that has previously been proposed
by other research (18). The CSK has been shown to down-
regulate the tyrosine kinase activity of the c-src oncoprotein
through tyrosine phosphorylation of the c-src carboxyl termi-
nus. The CSK gene could therefore potentially function as an
antioncogene. Myoui et al. (27) examined the role of CSK in
bone metastasis using an animal model with an inoculation
of breast cancer cells and reported that CSK was an essential
molecule for bone resorption by osteoclasts, which were cen-
tral players in osteolytic bone metastases. They suggested the
notion that CSK was a potential target molecule for design-
ing novel therapeutic interventions, especially for bone metas-
tases in breast cancer. In our study, CSK was down-regulated
in cancer tissue of seven cases, which suggested that they need-
ed to closer follow-up for bone metastasis. Identification of
such a target may improve the efficiency of developing ther-
apeutics for breast cancer.
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Fig. 2. Immunohistochemical stain for  -catenin in breast cancer. (A) Membranous pattern from case 1 (×200). (B) Aberrantly accumulat-
ed pattern in the nucleus and cytoplasm from case 5 (×400).
A BcDNA microarray provided a powerful alternative with an
unprecedented view scope in monitoring of the gene expres-
sion levels and led to discoveries of regulatory pathways in-
volved in complicated biological processes. Differences in gene
expression are likely to explain the phenotype variation. We
used it to answer the specific question whether could be dis-
tinguished by their gene expression profiles and whether these
could be related to differences in biological effects. Lin et al.
(10) reported that high  -catenin activity significantly corre-
lated with poor prognosis of the patients and was a strong and
independent prognostic factor in breast cancer. Lim et al. (28)
reported that aberrant expression of  -catenin was identified
in 79% of breast cancer and there was correlation of aberrant
expression of  -catenin with lymph node metastasis, survival
rate, and survival length in Korean patients with breast can-
cer.  -catenin is an executor of Wnt signaling. Components
of Wnt signaling pathway include proto-oncogene products,
such as  -catenin, tumor suppressor proteins, such as APC,
and Axin. It has been reported that Wnt genes are sometimes
overexpressed in human breast cancer and there is a growing
evidence that downstream components of the Wnt signaling
pathway are activated in a significant proportion of breast
tumors (29). Axin, a negative regulator of this pathway, pro-
motes phoasphorylation of serine/threonine in exon 3 of  -
catenin by forming a complex with APC and GSK-3 . Phos-
phorylated -catenin is quickly degraded via an ubiquitin-
proteasome pathway in the cytoplasm. Upon Wnt signaling,
phosphorylation of  -catenin functions as a transcriptional
regulator in the nucleus coupled with molecules of the Tcf/Lef
family (13, 14). Siah is the mammalian homolog of Drosophila
seven in absentia, required for formation of the R7 photore-
ceptor cells during eye development (30). Siah-1 mediated
downregulation of  -catenin was induced by p53, providing
a link between p53 and cell cycle regulation through a novel
-catenin degradation pathway (31). Our study indicated that
-catenin can be involved in breast cancer formation and/or
progression and may serve as a target for breast cancer therapy,
if we identified gene respect to regulatory pathways involved
in  -catenin expression. In this study, three cancer tissues show-
ing immunohistochemically aberrant accumulation of  -ca-
tenin in the nucleus and/or cytoplasm revealed down-regula-
tion of Siah and Axin genes and up-regulation of Wnt and c-
myc genes. Of the remaining seven cancer tissues without
aberrant  -catenin expression, four cases showed that the
results of these genes expression were vice versa. Although
the remaining three cases showed inconsistent findings, our
study revealed consistent findings of the mechanism of  -
catenin expression in tumorigenesis of breast cancer. However,
because the cases studied had short follow-up periods, we can-
not determine the relation between  -catenin expression and
prognostic significance.
We have analyzed whole cancer tissues in this study instead
of focusing only on cancer cells to better describe the entire
aspect of breast cancer, because breast cancer tissues as other
cancers generally contain multiple nonepithelial cell types
such as fibroblast, smooth muscle cell, endothelial cell, infil-
trating lymphocyte, and macrophage. Recent advances in
cancer research have revealed the relevance of epithelial-stro-
mal interaction including extracellular matrices, matrix met-
alloproteinases, and angiogenic factors in cancer progression
(32). Accordingly, targets of cancer therapeutics have been
recently extended from molecules of cancer origin to molecules
to stroma origin such as those related to angiogenesis and
matrix remodeling (33, 34). As this study, it was based on
whole tissue samples, the list of genes up-regulated in cancer
tissues contained and may still contain many genes for stroma.
With further functional study, potentially therapeutic target
molecules of stroma might be identified.
These results provide not only a new molecular basis for
understanding biological properties of breast cancer, but also
useful resources for future development of therapeutic targets
for breast cancer. To investigate the molecular understanding
of regulatory pathways involved in the complicated carcino-
genic processes, especially associated with the expression of
-catenin, a downstream effector of Wnt-mediated tumorige-
nesis in breast cancer, was also suggested. The genes suggested
by this analysis may serve as candidates for more detailed exam-
ination by using a larger number of clinical samples and veri-
fication at the protein level. 
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